Akero Therapeutics is advancing new medicines designed to treat serious metabolic diseases by restoring metabolic balance. The company's lead compound is AKR-001, a novel long-acting FGF21 analogue. Akero plans to begin Phase 2 clinical studies of AKR-001 for the treatment of NASH.

Company Name

Akero Therapeutics (AKRO)


South San Francisco, Calif.

Investment Stage

IPO June 2019